722 related articles for article (PubMed ID: 24647874)
1. A nomogram for predicting locoregional recurrence in primary breast cancer patients who received breast-conserving surgery after neoadjuvant chemotherapy.
Matsuda N; Hayashi N; Ohde S; Yagata H; Kajiura Y; Yoshida A; Suzuki K; Nakamura S; Tsunoda H; Yamauchi H
J Surg Oncol; 2014 Jun; 109(8):764-9. PubMed ID: 24647874
[TBL] [Abstract][Full Text] [Related]
2. Breast-conserving therapy after neoadjuvant chemotherapy: long-term results.
Beriwal S; Schwartz GF; Komarnicky L; Garcia-Young JA
Breast J; 2006; 12(2):159-64. PubMed ID: 16509842
[TBL] [Abstract][Full Text] [Related]
3. Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy.
Huang EH; Tucker SL; Strom EA; McNeese MD; Kuerer HM; Hortobagyi GN; Buzdar AU; Valero V; Perkins GH; Schechter NR; Hunt KK; Sahin AA; Buchholz TA
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):351-7. PubMed ID: 15890574
[TBL] [Abstract][Full Text] [Related]
4. Can we predict local recurrence in breast conserving surgery after neoadjuvant chemotherapy?
Cebrecos I; Córdoba O; Deu J; Xercavins J; Rubio IT
Eur J Surg Oncol; 2010 Jun; 36(6):528-34. PubMed ID: 20444571
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer.
Rouzier R; Pusztai L; Garbay JR; Delaloge S; Hunt KK; Hortobagyi GN; Berry D; Kuerer HM
Cancer; 2006 Oct; 107(7):1459-66. PubMed ID: 16948128
[TBL] [Abstract][Full Text] [Related]
6. Recurrence rates after DCE-MRI image guided planning for breast-conserving surgery following neoadjuvant chemotherapy for locally advanced breast cancer patients.
Garimella V; Qutob O; Fox JN; Long ED; Chaturvedi A; Turnbull LW; Drew PJ
Eur J Surg Oncol; 2007 Mar; 33(2):157-61. PubMed ID: 17085007
[TBL] [Abstract][Full Text] [Related]
7. T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy.
Garg AK; Strom EA; McNeese MD; Buzdar AU; Hortobagyi GN; Kuerer HM; Perkins GH; Singletary SE; Hunt KK; Sahin A; Schechter N; Valero V; Tucker SL; Buchholz TA
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):138-45. PubMed ID: 15093909
[TBL] [Abstract][Full Text] [Related]
8. Prognostic index score and clinical prediction model of local regional recurrence after mastectomy in breast cancer patients.
Cheng SH; Horng CF; Clarke JL; Tsou MH; Tsai SY; Chen CM; Jian JJ; Liu MC; West M; Huang AT; Prosnitz LR
Int J Radiat Oncol Biol Phys; 2006 Apr; 64(5):1401-9. PubMed ID: 16472935
[TBL] [Abstract][Full Text] [Related]
9. Loco-regional control after neo-adjuvant chemotherapy and conservative treatment for locally advanced breast cancer patients.
Levy A; Borget I; Bahri M; Arnedos M; Rivin E; Vielh P; Balleyguier C; Rimareix F; Bourgier C
Breast J; 2014; 20(4):381-7. PubMed ID: 24890310
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
[TBL] [Abstract][Full Text] [Related]
11. Locoregional recurrence of breast cancer in patients treated with breast conservation surgery and radiotherapy following neoadjuvant chemotherapy.
Min SY; Lee SJ; Shin KH; Park IH; Jung SY; Lee KS; Ro J; Lee S; Kim SW; Kim TH; Kang HS; Cho KH
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e697-705. PubMed ID: 21129858
[TBL] [Abstract][Full Text] [Related]
12. Is regional lymph node irradiation necessary in stage II to III breast cancer patients with negative pathologic node status after neoadjuvant chemotherapy?
Daveau C; Stevens D; Brain E; Berges O; Villette S; Moisson P; Gardner M; De la Lande B; Lasry S; Labib A; Le Scodan R
Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):337-42. PubMed ID: 20171795
[TBL] [Abstract][Full Text] [Related]
13. The safety of breast-conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy.
Peintinger F; Symmans WF; Gonzalez-Angulo AM; Boughey JC; Buzdar AU; Yu TK; Hunt KK; Singletary SE; Babiera GV; Lucci A; Meric-Bernstam F; Kuerer HM
Cancer; 2006 Sep; 107(6):1248-54. PubMed ID: 16862596
[TBL] [Abstract][Full Text] [Related]
14. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy.
Huang EH; Tucker SL; Strom EA; McNeese MD; Kuerer HM; Buzdar AU; Valero V; Perkins GH; Schechter NR; Hunt KK; Sahin AA; Hortobagyi GN; Buchholz TA
J Clin Oncol; 2004 Dec; 22(23):4691-9. PubMed ID: 15570071
[TBL] [Abstract][Full Text] [Related]
15. A validated web-based nomogram for predicting positive surgical margins following breast-conserving surgery as a preoperative tool for clinical decision-making.
Pleijhuis RG; Kwast AB; Jansen L; de Vries J; Lanting R; Bart J; Wiggers T; van Dam GM; Siesling S
Breast; 2013 Oct; 22(5):773-9. PubMed ID: 23462681
[TBL] [Abstract][Full Text] [Related]
16. Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience.
Chen AM; Meric-Bernstam F; Hunt KK; Thames HD; Oswald MJ; Outlaw ED; Strom EA; McNeese MD; Kuerer HM; Ross MI; Singletary SE; Ames FC; Feig BW; Sahin AA; Perkins GH; Schechter NR; Hortobagyi GN; Buchholz TA
J Clin Oncol; 2004 Jun; 22(12):2303-12. PubMed ID: 15197191
[TBL] [Abstract][Full Text] [Related]
17. High expression of post-treatment Ki-67 status is a risk factor for locoregional recurrence following breast-conserving surgery after neoadjuvant chemotherapy.
Yamazaki N; Wada N; Yamauchi C; Yoneyama K
Eur J Surg Oncol; 2015 May; 41(5):617-24. PubMed ID: 25771264
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant interstitial high-dose-rate (HDR) brachytherapy combined with systemic chemotherapy in patients with breast cancer.
Roddiger SJ; Kolotas C; Filipowicz I; Kurek R; Kuner RP; Martin T; Baltas D; Rogge B; Kontova M; Hoffmann G; Pollow B; Zamboglou N
Strahlenther Onkol; 2006 Jan; 182(1):22-9. PubMed ID: 16404517
[TBL] [Abstract][Full Text] [Related]
19. Breast-conserving surgery after tumor downstaging by neoadjuvant chemotherapy is oncologically safe for stage III breast cancer patients.
Shin HC; Han W; Moon HG; Im SA; Moon WK; Park IA; Park SJ; Noh DY
Ann Surg Oncol; 2013 Aug; 20(8):2582-9. PubMed ID: 23504119
[TBL] [Abstract][Full Text] [Related]
20. Comparison of risk of local-regional recurrence after mastectomy or breast conservation therapy for patients treated with neoadjuvant chemotherapy and radiation stratified according to a prognostic index score.
Huang EH; Strom EA; Perkins GH; Oh JL; Chen AM; Meric-Bernstam F; Hunt KK; Sahin AA; Hortobagyi GN; Buchholz TA
Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):352-7. PubMed ID: 16887286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
